Evidence map›Paper›PMID 36480052›Full record

ArticleJournal of neurology2023

Diffusion tensor imaging of the brain in Pompe disease.

Jan J A van den Dorpel, Marjolein H G Dremmen, Nadine A M E van der Beek, Dimitris Rizopoulos, Pieter A van Doorn, Ans T van der Ploeg, Ryan L Muetzel, Johanna M P van den Hout

Open access · hybridAbstract read
In one paragraph

Article in Journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Evaluation of Pompe Disease from a Broad and Systemic Perspective.Journal of clinical practice and research · 2026
    Article
  4. Article
  5. Neurological glycogen storage diseases and emerging therapeutics.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024
    Review
  6. Article
  7. Article
  8. Gene therapy for glycogen storage diseases.Journal of inherited metabolic disease · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jan J A van den DorpelCenter for Lysosomal and Metabolic Diseases, Department of Pediatrics, Erasmus MC University Medical Center Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0003-0948-7313
Marjolein H G DremmenDepartment of Radiology and Nuclear Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Nadine A M E van der BeekCenter for Lysosomal and Metabolic Diseases, Department of Neurology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Dimitris RizopoulosDepartment of Biostatistics, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Pieter A van DoornCenter for Lysosomal and Metabolic Diseases, Department of Neurology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Ans T van der PloegCenter for Lysosomal and Metabolic Diseases, Department of Pediatrics, Erasmus MC University Medical Center Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
Ryan L Muetzel *Department of Child and Adolescent Psychiatry/Psychology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Johanna M P van den Hout *Center for Lysosomal and Metabolic Diseases, Department of Pediatrics, Erasmus MC University Medical Center Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands. j.vandenhout@erasmusmc.nl.
Erasmus MC · NL

Funding

Prinses Beatrix Spierfonds W.F16-03Prinses Beatrix Spierfonds W.OR16-07Sophia Foundation for Medical Research (SSWO) S17-32Stichting Metakids 2016-063ZonMw 152001005
6 · The paper itself

Abstract

Enzyme replacement therapy has drastically changed prospects of patients with Pompe disease, a progressive metabolic myopathy. As classic infantile patients survive due to treatment, they exhibit progressive white matter abnormalities, while brain involvement in late-onset patients is not fully elucidated. To study the underlying microstructure of white matter, we acquired structural (T1, T2, FLAIR) and diffusion tensor imaging (DTI) of the brain in 12 classic infantile patients (age 5-20 years) and 18 late-onset Pompe patients (age 11-56 years). Structural images were scored according to a rating scale for classic infantile patients. Fractional anisotropy (FA) and mean diffusivity (MD) from classic infantile patients were compared to a reference population, using a Wilcoxon signed-rank, one sample test. Effect sizes (Hedges' G) were used to compare DTI metrics across different tracts. For late-onset patients, results were compared to (reported) tractography data on normal aging. In classic infantile patients, we found a significant lower FA and higher MD (p < 0.01) compared to the reference population. Large-association fibers were most severely affected. Classic infantile patients with advanced white matter abnormalities on structural MRI showed the largest deviations from the reference population. FA and MD were similar for younger and older late-onset patients in large WM-association fibers. We conclude that, while no deviations from typical neurodevelopment were found in late-onset patients, classic infantile Pompe patients showed quantifiable, substantially altered white matter microstructure, which corresponded with disease stage on structural MRI. DTI holds promise to monitor therapy response in future therapies targeting the brain.

Indexed as

Glycogen Storage Disease Type IIWhite MatterAdolescentAdultAnisotropyBrainChildChild, PreschoolDiffusion Magnetic Resonance ImagingDiffusion Tensor ImagingHumansMiddle AgedYoung AdultBrainDiffusion tensor imaging (DTI)MRIPompe diseaseWhite matter abnormalities

Identifiers

PMID36480052
PMCPMC9971081
OpenAlexW4310950345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.